**AMENDMENTS TO THE CLAIMS:**

This listing of claims will replace all prior versions, and listings, of claims in the application:

**LISTING OF CLAIMS:**

Claims 1 - 60. (Canceled)

Claims 61 - 64. (Canceled)

65. (Currently Amended) The pharmaceutical formulation of claim ~~61~~ 82, wherein the ~~fatty component is a sustained released component that~~ glyceryl behenate provides sustained release of the clarithromycin or clarithromycin derivative, and wherein the ~~hydrophilic component~~ hydroxypropyl methylcellulose forms a viscous layer in an aqueous medium through which the clarithromycin or clarithromycin derivative diffuses upon solubilization thereby effective to provide controlled release of the clarithromycin or clarithromycin derivative over about a twenty-four hour period.

Claims 66 - 69. (Canceled)

70. (Currently Amended) The pharmaceutical formulation of claim ~~69~~ 82, wherein the hydroxypropyl methylcellulose is low viscosity hydroxypropyl methylcellulose.

71. (Previously Presented) The pharmaceutical formulation of claim 70, wherein the hydroxypropyl methylcellulose has a viscosity of about 15 cP.

72. (Currently Amended) The pharmaceutical formulation of claim ~~61~~ 82, further comprising a surfactant.

73. (Previously Presented) The pharmaceutical formulation of claim 72, wherein the surfactant comprises sodium docusate.

74. (Currently Amended) The pharmaceutical formulation of claim ~~61~~ 82, further comprising a pH modulator.

75. (Previously Presented) The pharmaceutical formulation of claim 74, wherein the pH modulator comprises a phosphate buffer.

76. (Currently Amended) The pharmaceutical formulation of claim ~~61~~ 82 in tablet form.

77. (Previously Presented) The pharmaceutical formulation of claim 76, wherein the tablet is coated.

78. (Previously Presented) The pharmaceutical formulation of claim 77, wherein the coating is an acid-resistant coating.

79. (Currently Amended) The pharmaceutical formulation of claim 78, wherein the coating comprises ~~a mixture of HPMC and HPC~~ HPMC-phthalate.

80. (Currently Amended) A method for producing a controlled release pharmaceutical formulation, the method comprising:

a) forming a matrix comprising:

i) ~~a fatty component~~ glyceryl behenate comprising about 10-36 weight percent of the formulation;

ii) ~~a hydrophilic component~~ hydroxypropyl methylcellulose comprising about ~~5-18~~ 13-18 weight percent of the formulation;

iii) a clarithromycin component, or derivative thereof, comprising at least about ~~40~~ 42 weight percent of the formulation,

wherein the components are combined to allow the ~~fatty component~~ glyceryl behenate to form the matrix and wherein the ~~hydrophilic component~~ hydroxypropyl methylcellulose and the clarithromycin component are dispersed within the matrix; and

b) compressing the matrix into tablet form.

81. (Previously Presented) The method of claim 80, further comprising sieving the matrix prior to compressing the matrix into tablet form.

82. (New) A controlled release pharmaceutical formulation comprising a matrix, said matrix comprising:

a) glyceryl behenate comprising about 10-36 weight percent of the formulation;

b) hydroxypropyl methylcellulose comprising about 13-18 weight percent of the formulation and dispersed within the matrix; and

c) clarithromycin, or derivative thereof, comprising at least about 42 weight percent of the formulation and dispersed within the matrix,

wherein the glyceryl behenate, hydroxypropyl methylcellulose, and clarithromycin are combined under conditions suitable for generating the matrix, and wherein the matrix provides a controlled release formulation for the once daily administration of clarithromycin.

83. (New) The pharmaceutical formulation of claim 82, wherein the clarithromycin component comprises about 43 weight percent of the formulation.